EFFECTIVENESS OF ANTI-VEGF, FOCAL LASER, AND PRP FOR THE TREATMENT OF DIABETIC RETINOPATHY AND DIABETIC MACULAR EDEMA: SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

A search of the database identified 1,119 publications during the screening process, with 99 publications included in the systematic review and 95 publications used in the quantitative analysis. Literature quality analysis was performed using the RoB 2.0 tool and the ROBINS-1 V2 tool, while quantitative analysis was conducted using the RStudio application. The best improvement in BCVA was observed in Brolucizumab+Laser (MD 11.38, 95% CI 6.50–16.25), and the best reduction in central retinal thickness was observed in Aflibercept+Laser (MD -67.96, 95% CI -102.78 – -33.15). In conclusion, anti-VEGF agents can be used, and their efficacy is enhanced when monotherapy drugs such as Brolucizumab and Aflibercept are combined with Laser.

本研究经数据库检索，在文献筛选阶段共识别出1119篇文献，其中99篇被纳入系统评价，95篇被用于定量分析。文献质量评估采用偏倚风险评估工具2.0（RoB 2.0）与非随机研究偏倚风险评估工具V2（ROBINS-1 V2）开展，定量分析则通过RStudio软件完成。最佳矫正视力（Best Corrected Visual Acuity，BCVA）的最优改善效果见于布罗利珠单抗联合激光治疗组（均差MD=11.38，95%置信区间CI：6.50~16.25），而中心视网膜厚度的最优降低效果见于阿柏西普联合激光治疗组（均差MD=-67.96，95%置信区间CI：-102.78~-33.15）。综上，抗血管内皮生长因子（anti-VEGF）药物可应用于相关临床场景，当布罗利珠单抗、阿柏西普等单药治疗药物与激光治疗联用时，其临床疗效可得到显著提升。